Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium

Otávio Cabral-Marques*, Guido Moll, Rusan Catar, Beate Preuß, Lukas Bankamp, Ann Christin Pecher, Joerg Henes, Reinhild Klein, A. S. Kamalanathan, Reza Akbarzadeh, Wieke van Oostveen, Bettina Hohberger, Matthias Endres, Bryan Koolmoes, Nivine Levarht, Rudmer Postma, Vincent van Duinen, Anton Jan van Zonneveld, Jeska de Vries-Bouwstra, Cynthia FehresFlorian Tran, Fernando Yuri Nery do Vale, Kamilla Batista da Silva Souza, Igor Salerno Filgueiras, Lena F. Schimke, Gabriela Crispim Baiocchi, Gustavo Cabral de Miranda, Dennyson Leandro Mathias da Fonseca, Paula Paccielli Freire, Alexander M. Hackel, Hanna Grasshoff, Anja Kerstein-Stähle, Antje Müller, Ralf Dechend, Xinhua Yu, Frank Petersen, Franziska Sotzny, Thomas P. Sakmar, Hans D. Ochs, Kai Schulze-Forster, Harald Heidecke, Carmen Scheibenbogen, Yehuda Shoenfeld, Gabriela Riemekasten*

*Corresponding author for this work
1 Citation (Scopus)


G protein-coupled receptors (GPCR) are involved in various physiological and pathophysiological processes. Functional autoantibodies targeting GPCRs have been associated with multiple disease manifestations in this context. Here we summarize and discuss the relevant findings and concepts presented in the biennial International Meeting on autoantibodies targeting GPCRs (the 4th Symposium), held in Lübeck, Germany, 15–16 September 2022. The symposium focused on the current knowledge of these autoantibodies' role in various diseases, such as cardiovascular, renal, infectious (COVID-19), and autoimmune diseases (e.g., systemic sclerosis and systemic lupus erythematosus). Beyond their association with disease phenotypes, intense research related to the mechanistic action of these autoantibodies on immune regulation and pathogenesis has been developed, underscoring the role of autoantibodies targeting GPCRs on disease outcomes and etiopathogenesis. The observation repeatedly highlighted that autoantibodies targeting GPCRs could also be present in healthy individuals, suggesting that anti-GPCR autoantibodies play a physiologic role in modeling the course of diseases. Since numerous therapies targeting GPCRs have been developed, including small molecules and monoclonal antibodies designed for treating cancer, infections, metabolic disorders, or inflammatory conditions, anti-GPCR autoantibodies themselves can serve as therapeutic targets to reduce patients' morbidity and mortality, representing a new area for the development of novel therapeutic interventions.

Original languageEnglish
Article number103310
JournalAutoimmunity Reviews
Issue number5
Pages (from-to)103310
Publication statusPublished - 05.2023

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium'. Together they form a unique fingerprint.

Cite this